Massive pulmonary embolism after treatment with rFVIIa in a thrombocytopenic patient with acute myelogenous leukemia and intractable bleeding.
Mantzios
George
G
Tsirigotis
Panagiotis
P
Pappa
Vassiliki
V
Spirou
Konstantina
K
Giannopoulou
Vassiliki
V
Kaitsa
Irene
I
Girkas
Konstantinos
K
Papageorgiou
Efstathios
E
Dervenoulas
John
J
D000208:Acute Disease; D000368:Aged; D001803:Blood Transfusion; D003131:Combined Modality Therapy; D005167:Factor VII / Q000009:adverse effects* / Q000627:therapeutic use; D015942:Factor VIIa; D005260:Female; D005268:Femoral Vein; D005440:Fluid Therapy; D006471:Gastrointestinal Hemorrhage / Q000188:drug therapy*; D006490:Hemostatics / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007951:Leukemia, Myeloid / Q000150:complications*; D011655:Pulmonary Embolism / Q000139:chemically induced*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D016879:Salvage Therapy; D013920:Thrombocythemia, Essential / Q000150:complications*; D015912:Thrombolytic Therapy; D019851:Thrombophilia / Q000150:complications*; D013924:Thrombophlebitis / Q000139:chemically induced
D006490:Hemostatics; D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa